Legislative committee sends S.154 for actuarial study after testimony on biomarker testing
Witnesses including the Department of Vermont Health Access, the Alzheimer’s Association and insurers told a legislative committee that biomarkers can speed Alzheimer’s and cancer diagnoses but that Vermont needs an actuarial analysis of costs and coverage. The committee agreed to refine language and task DFR with the study, due Jan. 15, 2027.
The full story
A legislative committee on April 9 moved S.154 — legislation about insurance coverage and a fiscal study of biomarker testing — to an actuarial review after testimony from state health officials, patient advocates and insurers.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
Keep reading for free
Create a free account to finish this story and see the video, transcript and key details.
Continue with GoogleContinue with emailAlready have an account? Log in